Lidocaine (injection): Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
Line 6: | Line 6: | ||
'''''For patient information, click <u>[[Lidocaine (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Lidocaine (patient information)|here]]'''''</u>. | ||
{{SB}} | |||
{{SB}} XYLOCAINE | |||
==Overview== | ==Overview== |
Revision as of 17:57, 10 March 2014
Lidocaine |
---|
XYLOCAINE® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Clinical Trials on Lidocaine |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here.
Synonyms / Brand Names: XYLOCAINE
Overview
Category
FDA Package Insert[1]
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages